Hospital Vall d'Hebron-ko ikertzaileekin lankidetzan egindako argitalpenak (33)

2024

  1. Prognostic and therapeutic monitoring value of plasma and urinary cytokine profile in primary membranous nephropathy: the STARMEN trial cohort

    Clinical Kidney Journal, Vol. 17, Núm. 8

  2. Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia

    Kidney International Reports, Vol. 9, Núm. 5, pp. 1419-1428

2023

  1. Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

    Kidney360, Vol. 4, Núm. 5, pp. 659-672

  2. Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation

    Nephrology Dialysis Transplantation, Vol. 38, Núm. 1, pp. 222-235

  3. The coexistence of diabetic retinopathy and diabetic nephropathy is associated with worse kidney outcomes

    Clinical Kidney Journal, Vol. 16, Núm. 10, pp. 1656-1663

2022

  1. C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 11, pp. 2128-2137

  2. Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy

    Clinical Kidney Journal, Vol. 15, Núm. 9, pp. 1737-1746

  3. Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, Núm. 7, pp. 1270-1280

2021

  1. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

    Kidney International Reports, Vol. 6, Núm. 6, pp. 1603-1613

  2. The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease

    Kidney International Reports, Vol. 6, Núm. 9, pp. 2392-2403

  3. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

    Kidney International, Vol. 99, Núm. 4, pp. 986-998

  4. Validation of a Histologic Scoring Index for C3 Glomerulopathy

    American Journal of Kidney Diseases, Vol. 77, Núm. 5, pp. 684-695.e1

2020

  1. Risk factors for non-diabetic renal disease in diabetic patients

    Clinical Kidney Journal, Vol. 13, Núm. 3, pp. 380-388

2019

  1. Complement activation and thrombotic microangiopathies

    Clinical Journal of the American Society of Nephrology, Vol. 14, Núm. 12, pp. 1719-1732

  2. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome

    Kidney International, Vol. 96, Núm. 4, pp. 995-1004

2018

  1. Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients

    Kidney International Reports, Vol. 3, Núm. 1, pp. 122-132

2017

  1. Elevated factor H–related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy

    Kidney International, Vol. 92, Núm. 4, pp. 953-963

2016

  1. Altered underlying renal tubular function in patients with chronic hepatitis B receiving nucleos(t)ide analogs in a real-world setting the MENTE study

    Journal of Clinical Gastroenterology, Vol. 50, Núm. 9, pp. 779-789

2015

  1. A european multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: The STARMEN study

    Clinical Kidney Journal, Vol. 8, Núm. 5, pp. 503-510

  2. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis

    Kidney International, Vol. 88, Núm. 5, pp. 1153-1160